Catalent Pharma Solutions has entered a commercial supply agreement to support the global commercial product launch of Palatin Technologies’ bremelanotide pen injector product for the treatment of female sexual dysfunction (FSD).
 
Bremelanotide, a subcutaneous injectable peptide melanocortin receptor agonist, is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. Phase III clinical trials are underway, with a commercial launch anticipated in 2018.
 
The bremelanotide pen devices will be produced at Catalent’s 265,000-sq.-ft., sterile fill finish facility in Brussels, Belgium.
 
“We are pleased that Palatin has chosen to partner with Catalent to commercialize this new and innovative treatment,” said Jonathan Arnold, Catalent’s vice president and general manager for Advanced Delivery Technologies. “Catalent provides flexible manufacturing solutions to meet our customers’ unique program requirements, and our expertise in sterile filling, device and delivery technologies, combined with our packaging capabilities, will facilitate bringing this important product to market faster.”
 
“We selected Catalent as our partner because of their proven expertise in custom sterile manufacturing solutions, and their track record of successful new product introductions,” added Stephen T. Wills, chief financial officer and chief operating officer of Palatin. “Catalent provides the infrastructure, technical expertise and flexibility to support commercialization of this novel product.”

Visit Catalent at Tables 71, 72